

October 9, 2020

Dear Cystinosis Community:

Leadiant Biosciences, Inc. recently informed the FDA that CYSTARAN® (cysteamine ophthalmic solution) 0.44% eye drops will go into shortage by the end of October.

In addition to the FDA, we have communicated the shortage to AllianceRx Walgreens Prime, the specialty pharmacy where patients normally fill their prescriptions, to patient advocacy organizations, and to their physicians.

Leadiant contracts with an independent manufacturer to make CYSTARAN. That company is undergoing restructuring under Chapter 11 of the Bankruptcy Code, which has affected the continuous manufacture of CYSTARAN at this time.

Patients should speak with their healthcare provider about how this will impact their treatment plan.

We are doing everything possible to bring CYSTARAN back to patients as quickly as possible. We are continuing to work with our current manufacturing partner with the goal of restarting production quickly. At the same time, we have identified an alternate manufacturer for CYSTARAN.

We will continue to communicate with the patients' specialty pharmacy and doctors about any updates, including a more precise timeline for when CYSTARAN will be available, and post updates to CYSTARAN.com and Leadiant.com.

Please know that everyone at Leadiant is committed to have CYSTARAN available to patients as quickly as possible. We have been dedicated to the cystinosis community for more than 20 years, and we are dedicated to working with you through this time.

If you have any additional questions regarding this shortage, please call AllianceRx Walgreens Prime at 877-534-9627 or Lesli King at 301-670-5450, Lesli.King@Leadiant.com.

Thank you,
Your Leadiant Team